Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice

Journal of Clinical Investigation

Volumn 106, Issue 4, 2000, Pages 523-531

  Li, Andrew C ^a   Brown, Kathleen K ^b   Silvestre, Mercedes J ^c   Willson, Timothy M ^b   Palinski, Wulf ^c   Glass, Christopher K ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CD36 ANTIGEN; FATTY ACID; GELATINASE B; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BONE MARROW; CONTROLLED STUDY; DRUG EFFECT; EXTRAMEDULLARY HEMATOPOIESIS; FEMALE; GENE EXPRESSION; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0033864582     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI10370     Document Type: Article

References (43)

1. Kannel, W., and McGee, D. 1979. Diabetes and cardiovascular disease: the Framingham study. JAMA. 241:2035-2038.
2. Uusitupa, M., Niskanen, L., and Siitonen, O. 1990. 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin levels, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation. 82:27-36.
3. Steinberg, D., Parthasarathy, S., Carew, T.E., Khoo, J.C., and Witztum, J.L. 1989. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320:915-924.
4. Napoli, C., et al. 1997. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J. Clin. Invest. 100:2680-2690.
5. Kodama, T., Reddy, P., Kishimoto, C., and Krieger, M. 1988. Purification and characterization of a bovine acetyl low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA. 85:9238-9242.
6. Endemann, G., et al. 1993. CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem. 268:11811-11816.
7. Ramprasad, M.P., Terpstra, V., Kondratenko, N., Quehenberger, O., and Steinberg, D. 1996. Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA. 93:14833-14838.
8. Ross, R. 1986. The pathogenesis of atherosclerosis. N. Engl. J. Med. 314:488-500.
9. Ross, R. 1999. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340:115-126.
10. Boring, L., Gosling, J., Cleary, M., and Charo, I.F. 1998. Decreased lesion formation in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 394:894-897.
11. Gosling, J., et al. 1999. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J. Clin. Invest. 103:773-778.
12. Suzuki, H., et al. 1997. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature. 386:292-296.
13. Febraio, M., et al. 2000. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J. Clin. Invest. 105:1049-1056.
14. Barnes, P.J., and Karin, M. 1997. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336:1066-1071.
15. Sato, H., Kita, M., and Seiki, M. 1993. v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines. J. Biol. Chem. 268:23460-23468.
16. Ricote, M., et al. 1998. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA. 95:7614-7619.
17. Marx, N., Sukhova, G., Murphy, C., Libby, P., and Plutzky, J. 1998. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am. J. Pathol. 153:17-23.
18. Jackson, S.M., et al. 1999. Peroxisome proliferator-activared receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler. Thromb. Vasc. Biol. 19:2094-2104.
19. Tontonoz, P., Nagy, L., Alvarez, J.G.A., Thomazy, V.A., and Evans, R.M. 1998. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 93:241-252.
20. Pasceri, V., Wu, H.D., Willerson, J.T. and Yeh, E.T. 2000. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation. 101:235-238.
21. Nagy, L., Tontonoz, P., Alvarez, J.G.A., Chen, H., and Evans, R.M. 1998. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR-gamma. Cell. 91:229-240.
22. 2 is a ligand for the adipocyte determination factor PPARγ. Cell. 83:803-812.
23. Kliewer, S.A., et al. 1997. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc. Natl. Acad. Sci. USA. 94:4318-4323.
24. Barak, Y., et al. 1999. PPARγ is required for placental, cardiac, and adipose tissue development. Mol. Cell. 4:585-595.
25. Kubota, N., et al. 1999. PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell. 4:597-609.
26. Rosen, E.D., et al. 1999. PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell. 4:611-617.
27. Nolan, J.J., Ludvik, B., Beerdsen, P., Joyce, M., and Olefsky, J. 1994. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J Med. 331:1188-1193.
28. Jiang, C., Ting, A.T., and Seed, B. 1998. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 391:82-86.
29. Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J., and Glass, C.K. 1998. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 391:79-82.
30. Su, C.G., et al. 1999. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J. Clin. Invest. 104:383-389.
31. Sheehan, D.C., and Hrapchak, B.B. 1980. Theory and practice of histotechnology. C.V. Mosby Co., St. Louis, Missouri, USA. 481 pp.
32. Tangirala, R.K., Rubin, E.M., and Palinski, W. 1995. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apoprotein E-deficient mice. J. Lipid Res. 36:1-9.
33. Willson, T., Brown, P., Sternbach, D., and Henke, B. 2000. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43:527-550.
34. Fruebis, J., Gonzales, V., Silvestre, M., and Palinski, W. 1997. Effect of probucol treatment on gene expression of VCAM-1, MCP-1 and M-CSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 17:1289-1302.
35. Tsimikas, S., Shortal, B.P., Witztum, J.L., and Palinski, W. 2000. In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. Arterioscler. Thromb. Vasc. Biol. 20:689-697.
36. Holness, C.L., and Simmons, D.L. 1993. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood. 81:1607-1613.
37. Goetze, S., et al. 1999. PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J. Cardiovasc. Pharmacol. 33:798-806.
38. Libby, P., Sukhova, G., Lee, R.T., and Galis, Z.S. 1995. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J. Cardiovasc. Pharmacol. 25(Suppl. 2):S9-S12.
39. Murao, K., et al. 1999. Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells. FEBS Lett. 454:27-30.
40. Law, R.E., et al. 1996. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J. Clin. Invest. 98:1897-1905.
41. Staels, B., et al. 1998. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature. 393:790-793.
42. Merat, S., Casanada, F., Sutphin, M., Palinski, W., and Reaven, P.D. 1999. Western-type diets induce insulin resistance and hyperinsulinemia in LDL receptor-deficient mice but do not increase aortic atherosclerosis compared with normoinsulinemic mice in which similar plasma cholesterol levels are achieved by a fructose-rich diet. Arterioscler. Thromb. Vasc. Biol. 19:1223-1230.
43. Roe, E.B., Chiu, K.M., and Arnaud, C.D. 2000. Selective estrogen receptor modulators and postmenopausal health. Adv. Intern. Med. 45:257-278.